These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35357972)

  • 21. Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells.
    Wolf C; Smith S; van Wijk SJL
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.
    Razafinjatovo C; Bihr S; Mischo A; Vogl U; Schmidinger M; Moch H; Schraml P
    BMC Cancer; 2016 Aug; 16():638. PubMed ID: 27530247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
    Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
    J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
    Curry L; Soleimani M
    Future Oncol; 2024; 20(18):1251-1266. PubMed ID: 38639572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
    Gao W; Li W; Xiao T; Liu XS; Kaelin WG
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolyl Hydroxylase 3 Knockdown Accelerates
    Zacharias NM; Wang L; Maity T; Li L; Millward SW; Karam JA; Wood CG; Navai N
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.
    Suárez C; Vieito M; Valdivia A; González M; Carles J
    Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma.
    Zhao Z; Chen C; Lin J; Zeng W; Zhao J; Liang Y; Tan Q; Yang C; Li H
    Mol Med Rep; 2016 Sep; 14(3):2785-90. PubMed ID: 27485825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Silico Exploration of AHR-HIF Pathway Interplay: Implications for Therapeutic Targeting in ccRCC.
    Gregoris F; Minervini G; Tosatto SCE
    Genes (Basel); 2024 Sep; 15(9):. PubMed ID: 39336758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
    Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.
    Kucejova B; Peña-Llopis S; Yamasaki T; Sivanand S; Tran TA; Alexander S; Wolff NC; Lotan Y; Xie XJ; Kabbani W; Kapur P; Brugarolas J
    Mol Cancer Res; 2011 Sep; 9(9):1255-65. PubMed ID: 21798997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.
    Vanharanta S; Shu W; Brenet F; Hakimi AA; Heguy A; Viale A; Reuter VE; Hsieh JJ; Scandura JM; Massagué J
    Nat Med; 2013 Jan; 19(1):50-6. PubMed ID: 23223005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
    Choueiri TK; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Michaelson MD; Appleman LJ; Thamake S; Perini RF; Zojwalla NJ; Jonasch E
    Nat Med; 2021 May; 27(5):802-805. PubMed ID: 33888901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer.
    Kaelin WG
    J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 36106637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma.
    Langbein LE; El Hajjar R; He S; Sementino E; Zhong Z; Jiang W; Leiby BE; Li L; Uzzo RG; Testa JR; Yang H
    Cancer Lett; 2022 Oct; 547():215885. PubMed ID: 35995140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.